Abstract
Nuclear Factor-Kappa B (NF-κB) is a transcription factor whose inappropriate activation may result in the development of a number of diseases including cancer, inflammation, neurodegeneration and AIDS. Recent studies on NF- κB mediated pathologies, made therapeutic interventions leading to its inhibition an emerging theme in pharmaceutical research. NF-κB resides in the cytoplasm and is activated by several time-dependent factors, leading to proteasomedependent degradation of its inhibitory protein (IκB), resulting in free NF-κB (p50 and p65 subunits, involved in disease states), which binds to target DNA sites, further resulting in enhanced transcription of several disease associated proteins. The complex pathway of NF-κB, finally leading to its DNA binding, has attracted several approaches interfering with this pathway. One such approach is that of a direct covalent modification of NF-κB. In this article, we present a critical review of the pharmacological agents that have been studied as inhibitors of NF-κB by covalently modifying redox-regulated cysteine residues in its subunits, ultimately resulting in the inhibition of κB DNA recognition and binding. Beginning with a general overview of NF-κB pathway and several possibilities of chemical interventions, the significance of redoxregulation in NF-κB activation and DNA binding is presented. Further, protein S-thiolation, S-nitrosylation and irreversible covalent modification are described as regular biochemical events in the cell, having provided a guideline for the development of NF-κB inhibitors discussed further. Although just a handful of inhibitors, with most of them being alkylating agents have been studied in the present context, this approach presents potential for the development of a new class of NF-κB-inhibitors.
Keywords: Nuclear Factor-Kappa B, Cysteine, S-thiolation, S-nitrosylation, Covalent Modification, Alkylating Agents
Current Medicinal Chemistry
Title: Direct Covalent Modification as a Strategy to Inhibit Nuclear Factor-Kappa B
Volume: 16 Issue: 32
Author(s): V. Pande, S. F. Sousa and M. J. Ramos
Affiliation:
Keywords: Nuclear Factor-Kappa B, Cysteine, S-thiolation, S-nitrosylation, Covalent Modification, Alkylating Agents
Abstract: Nuclear Factor-Kappa B (NF-κB) is a transcription factor whose inappropriate activation may result in the development of a number of diseases including cancer, inflammation, neurodegeneration and AIDS. Recent studies on NF- κB mediated pathologies, made therapeutic interventions leading to its inhibition an emerging theme in pharmaceutical research. NF-κB resides in the cytoplasm and is activated by several time-dependent factors, leading to proteasomedependent degradation of its inhibitory protein (IκB), resulting in free NF-κB (p50 and p65 subunits, involved in disease states), which binds to target DNA sites, further resulting in enhanced transcription of several disease associated proteins. The complex pathway of NF-κB, finally leading to its DNA binding, has attracted several approaches interfering with this pathway. One such approach is that of a direct covalent modification of NF-κB. In this article, we present a critical review of the pharmacological agents that have been studied as inhibitors of NF-κB by covalently modifying redox-regulated cysteine residues in its subunits, ultimately resulting in the inhibition of κB DNA recognition and binding. Beginning with a general overview of NF-κB pathway and several possibilities of chemical interventions, the significance of redoxregulation in NF-κB activation and DNA binding is presented. Further, protein S-thiolation, S-nitrosylation and irreversible covalent modification are described as regular biochemical events in the cell, having provided a guideline for the development of NF-κB inhibitors discussed further. Although just a handful of inhibitors, with most of them being alkylating agents have been studied in the present context, this approach presents potential for the development of a new class of NF-κB-inhibitors.
Export Options
About this article
Cite this article as:
Pande V., Sousa F. S. and Ramos J. M., Direct Covalent Modification as a Strategy to Inhibit Nuclear Factor-Kappa B, Current Medicinal Chemistry 2009; 16 (32) . https://dx.doi.org/10.2174/092986709789578222
DOI https://dx.doi.org/10.2174/092986709789578222 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIV Shedding in Cervico-Vaginal Secretions in Pregnant Women
Current HIV Research Lipid Nanoparticles and their Application in Nanomedicine
Current Pharmaceutical Biotechnology Regulation of Apoptosis and Activity of the Osteoclast
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry Selective Photodynamic Effects on Breast Cancer Cells Provided by p123 Pluronic®- Based Nanoparticles Modulating Hypericin Delivery
Anti-Cancer Agents in Medicinal Chemistry From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry 2-Arylbenzimidazoles as Antiviral and Antiproliferative Agents-Part 1
Medicinal Chemistry Ubiquitin Carboxyl Hydrolase L1 Significance for Human Diseases
Protein & Peptide Letters Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Cancer Stem Cells and Therapeutic Perspectives
Current Medicinal Chemistry Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Multidrug Resistance in Cancer Chemotherapy and Xenobiotic Protection Mediated by the Half ATP-Binding Cassette Transporter ABCG2
Current Medicinal Chemistry - Anti-Cancer Agents Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Autophagy Driven Extracellular Vesicles in the Leukaemic Microenvironment
Current Cancer Drug Targets GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets